García García, M. C., Gómez Cañas, M., Burgaz García-Oteyza, S., Gómez Gálvez, Y., Palomo Garo, C., Campo, S., . . . Fernández Ruiz, J. J. (2018). Benefits of VCE-003.2, a cannabigerol quinone derivative, against inflammation-driven neuronal deterioration in experimental Parkinson’s disease: Possible involvement of different binding sites at the PPARγ receptor.
Citación estilo ChicagoGarcía García, María Concepción, et al. Benefits of VCE-003.2, a Cannabigerol Quinone Derivative, against Inflammation-driven Neuronal Deterioration in Experimental Parkinson’s Disease: Possible Involvement of Different Binding Sites At the PPARγ Receptor. 2018.
Cita MLAGarcía García, María Concepción, et al. Benefits of VCE-003.2, a Cannabigerol Quinone Derivative, against Inflammation-driven Neuronal Deterioration in Experimental Parkinson’s Disease: Possible Involvement of Different Binding Sites At the PPARγ Receptor. 2018.